Advanced glycation end products induce blood-retinal barrier dysfunction in normoglycemic rats

Molecular Cell Biology Research Communications

Volumn 3, Issue 6, 2000, Pages 380-388

  Stitt, Alan W ^a   Bhaduri, Tisha ^a   McMullen, C B Tara ^a   Gardiner, Thomas A ^a   Archer, Desmond B ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Advanced glycation end products; Blood retinal barrier; Diabetic retinopathy; Retina; Vascular endothelial growth factor

Indexed keywords

ADVANCED GLYCATION END PRODUCT; MESSENGER RNA; VASCULOTROPIN;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD RETINA BARRIER; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC RETINOPATHY; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; RETINA ISCHEMIA; RETINOPATHY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOUTHERN BLOTTING; TRANSMISSION ELECTRON MICROSCOPY;

ANIMALIA;

EID: 0033733768     PISSN: 15224724     EISSN: None     Source Type: Journal    
DOI: 10.1006/mcbr.2000.0243     Document Type: Article

References (55)

1. Early changes in diabetic retinopathy: Capillary loss and blood-retina barrier permeability in relation to metabolic control
2. Studies on retinal neovascularization. Friedenwald Lecture
3. Studies on the permeability of the blood-retinal barrier. I. On the existence, development, and site of a blood-retinal barrier
4. Progression of retinopathy and alteration of the blood-retinal barrier in patients with type 2 diabetes: A 7-year prospective follow-up study
5. Vascular permeability factor: A unique regulator of blood vessel function
6. Vascular endothelial growth factor and vascular permeability changes in human diabetic retinopathy
7. Cellular mechanisms of blood-retinal barrier dysfunction in macular edema
8. Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy
9. Localization of vascular endothelial growth factor in human retina and choroid
10. Advanced glycation end products: Impact on diabetic complications
11. Recent progress on the biologic and clinical significance of advanced glycosylation end products
12. Collagen aging in vitro by nonenzymatic glycosylation and browning
13. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications
14. Secondary intervention with aminoguanidine retards the progression of diabetic retinopathy in the rat model
15. The relationship of glycaemic level to advanced glycation end-product (AGE) accumulation and retinal pathology in the spontaneous diabetic hamster
16. Anti-glycated albumin therapy ameliorates early retinal microvascular pathology in db/db mice
17. Diabetic retinopathy risk correlates with intracellular concentrations of the glycoxidation product N(epsilon)-(carboxymethyl) lysine independently of glycohaemoglobin concentrations
18. Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats
19. Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties
20. Acute modulation of albumin microvascular leakage by advanced glycation end products in microcirculation of diabetic rats in vivo
21. Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: A model for diabetic and aging complications
22. Advanced glycation end products induce expression of vascular endothelial growth factor by retinal Muller cells
23. Advanced glycation end products increase retinal vascular endothelial growth factor expression
24. The relationship between accumulation of advanced glycation end products and expression of vascular endothelial growth factor in human diabetic retinas
25. Upregulation of retinal vascular endothelial growth factor mRNAs in spontaneously diabetic rats without ophthalmoscopic retinopathy. A possible participation of advanced glycation end products in the development of the early phase of diabetic retinopathy
26. Immunochemical detection of advanced glycosylation end products in vivo
27. Autoantibody against N(epsilon)-(carboxymethyl)lysine: An advanced glycation end product of the Maillard reaction
28. Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose
29. Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycosylation end products is mediated via platelet-derived growth factor
30. Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats
31. Expression of vascular endothelial growth factor (VEGF) and its receptors is regulated in eyes with intraocular tumours
32. Advanced glycation end products upregulate gene expression found in diabetic glomerular disease
33. Diabetic retinopathy
34. Ultrastructure of retinal vessels in diabetic patients
35. Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: Vascular endothelial growth factor decreases occludin in retinal endothelial cells
36. Vascular permeability factor/endothelial cell growth factor-mediated permeability occurs through disorganization of endothelial junctional proteins
37. Electron microscopic evidence for the mechanism of blood-retinal barrier breakdown in diabetic rabbits: Comparison with magnetic resonance imaging
38. Surface-associated vesicles in retinal arterioles and venules
39. VEGF-induced permeability increase is mediated by caveolae
40. Transcellular gaps in microvascular walls of frog and rat when permeability is increased by perfusion with the ionophore A23187
41. Vesiculo-vacuolar organelles and the regulation of venule permeability to macromolecules by vascular permeability factor, histamine, and serotonin
42. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis
43. Transcapillary transport of solute by the endothelial vesicular system: Evidence from thin serial section analysis
44. The caveolae membrane system
45. Expression of vascular endothelial growth factor in the human retina and in nonproliferative diabetic retinopathy
46. The biology of vascular endothelial growth factor
47. Vascular endothelial growth factor plays a role in hyperpermeability of diabetic retinal vessels
48. The relation between expression of vascular endothelial growth factor and breakdown of the blood-retinal barrier in diabetic rat retinas
49. Blood-ocular barrier breakdown in eyes with ocular melanoma. A potential role for vascular endothelial growth factor/vascular permeability factor
50. Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1)
51. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor
52. Vascular endothelial growth factor induces endothelial fenestrations in vitro
53. Ultrastructural localization of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) to the albuminal plasma membrane and vesiculovacuolar organelles of tumor microvascular endothelium
54. Caveolae and vesiculo-vacuolar organelles in bovine capillary endothelial cells cultured with VPF/VEGF on floating Matrigel-collagen gels
55. Endothelial fenestrae in proliferative diabetic retinopathy